IBCL-328 Follicular Lymphoma: Concentric Study in the Hematology Department of the IBN ROCHD University Hospital Center

• Published in: Clinical lymphoma, myeloma and leukemia Vol. 23; p. S452
• Main Authors: Maataoui-Belabbes, Hajar, Qachouh, Meryem, Moufid, Nassima, Benmoussa, Amine, Lamchahab, Mouna, Rachid, Mohamed, Cherkaoui, Siham, Khoubila, Nisrine, Madani, Abdellah
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.09.2023
• Subjects: follicular lymphoma; indolent B cell lymphoma; maintenance; rituximab; stem cell transplantation; indolent B cell lymphoma; follicular lymphoma; maintenance; stem cell transplantation; rituximab
• ISSN: 2152-2650; 2152-2669
• DOI: 10.1016/S2152-2650(23)01358-7

Follicular lymphoma (FL) is a systemic neoplasm of the lymphoid tissue displaying germinal center B cell differentiation. It represents 5% of all haematological neoplasms and 20-25%of all new non-Hodgkin lymphoma. Descriptive retrospective study carried out at the Hematology Department in Casablanca. From January 2018 to December 2022, 33 patients with newly diagnosed FL. The median age was 54 years [35-80] sex-ratio M/F 1.2. The most common symptomatology was tumor syndrome (30 cases) with B signs in 17 cases. Spinal cord compression, dyspnea and convulsion was respectively inaugural in one patient. Scan PET. The location of the biopsy was lymph node in 27 patients, skin, lacrymal gland, eyelid, maxillary bone, oropharynx and spinal cord in one case, respectively. The histopathological grade was grade 1 in 3 patients, grade 2 in one patient, grade 1 and 2 in 22 cases and 3A in 7 patients. Distribution of stages was: 2 II, 8 III and 23 IV. Within stage IV, the involvement interest bone marrow (9 cases), bone (5 patients), lung (6), liver (4), spinal cord (1), oropharynx (2), tonsils (1) and cutaneous (1). 17 patients had GELF score ≥2 and 22 patients had FLIPI index ≥2. 10 patients required a cytoreductive COP with a good response in 3 patients. wait and see attitude was opted in 2 patients for an average of 7 months before requiring treatment. The protocols used in first line were: RCHOP in 26 patients treated with courses of high-dose methotrexate in 1 case, RCVP in 4 patients (rituximab was not available in one patient at 2 first courses) and R-miniCHOP in 3 patients. Only 5 patients have received rituximab maintenance for 2 years. Complete remission (CR) rate was 79% (26). 9% (3) in partial remission and 12% (4) in therapeutic failure requiring salvage therapy. Only 2 patients have received stem-cell transplantation. 12 patients had a relapse after an average 2.6 years [3month-4.5years] including an early relapse in an autograft patient. Outcomes for FL with R-CHOP are encouraging. Most of our patients have not received rituximab maintenance for lack of means. Refractory and relapsed disease in autograft patients constitutes a therapeutic challenge.